2α,3α-Epithio-5α-androstan-17β-yl 1-Methoxycyclopentyl Ether in the Treatment of Advanced Breast Cancer —A Preliminary Clinical Trial—
KUMAOKA, SOICHI; TAKATANI, OSAMU; YOSHIDA, MINORU; MIURA, SHIGETO; TAKAO, TETSUTO; HAMANAKA, YÜJI; IZUO, MASARU; OKADA, TADAKAZU; KUMAOKA SOICHI; National Cancer Center Research Institute; TAKATANI OSAMU; National Cancer Center Hospital; YOSHIDA MINORU; Aichi Cancer Center Hospital; MIURA SHIGETO; Aichi Cancer Center Hospital; TAKAO TETSUTO; First Department of Surgery, Osaka University Medical School; HAMANAKA YÜJI; First Department of Surgery, Osaka University Medical School; IZUO MASARU; Department of Surgery, Gunma University, School of Medicine; OKADA TADAKAZU; Department of Surgery, Gunma University, School of Medicine
Журнал:
Japanese Journal of Clinical Oncology
Дата:
1974
Аннотация:
A new orally active anti-estrogenic steroid, 2α,3α-epithio-5α-androstan-17β-yl 1-methoxycyclopentyl ether (10364-S) was given to 41 advanced breast cancer patients. Most patients were given a daily dose of 20 mg. The study was preliminary and not a controlled trial using an already proven androgenic steroid. The remission rate on giving this compound to advanced breast cancer was 11/41 or 26.8% and the average duration of the remission was 10.5 months.Hoarseness (8/41, 19.5%) and hirsutism (5/41, 12.2%) were relatively often seen as virilizing side effects. No unfavorable effects on the hematopoietic organs, the liver or on calcium metabolism were recognized in the study.
206.9Кб